Companies Cryptocurrencies
ChemoCentryx Inc
ChemoCentryx Inc
Exchange: Nasdaq Global Select
IPO Date: 08/02/2012
CEO: Dr. Thomas Schall
Biotechnology Healthcare 🔗
  • CCXI
  • 19.2
  • 1366913280
    market cap
  • 0.03000069
If you bought

shares of ChemoCentryx Inc (CCXI) on
You would have made
Old Price $12 Current Price $12

ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. The company is headquartered in Mountain View, California and currently employs 76 full-time employees. The firm is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).

Address: 850 Maude Ave Mountain View CALIFORNIA 94043

Stay updated.